What Adriblastina Treats: Main Uses and Benefits

Adriblastina (Doxorubicin) is a systemically applied medication that is commonly used to manage serious malignant conditions (cancers). Its therapeutic relevance is focused on managing the conditions associated with systemic imbalance, rather than on providing temporary relief for common, mild symptoms.

---

The medication is indicated for various blood and lymph cancers like Acute Leukemias and Lymphomas, as well as various solid tumors such as metastatic breast cancer, ovarian carcinoma, and certain sarcomas. It is also applied in high-risk scenarios to help manage the risk of future disease return (adjuvant therapy) and for specific pediatric malignancies like Wilms' Tumor and Neuroblastoma. This application helps address the tumor burden and plays a role in managing symptoms related to disease progression. The goal is to support the management of the malignant disease, which helps provide support that contributes to easing the overall symptom load caused by the condition.

---

Quick Fact: Support for Symptom Burden Adriblastina supports patients by providing support for the overall systemic condition to help address the conditions associated with heightened physiological activity, which assists with maintaining functional stability during difficult symptomatic periods.

Adriblastina, which contains the active substance doxorubicin, is a potent chemotherapy agent used to treat various cancers, including certain types of leukemia, lymphoma, and solid tumors such as breast, ovarian, and lung carcinoma. This medicine is administered under the strict supervision of a physician experienced in cancer chemotherapy.

General Guidelines for Use

Adriblastina is generally used in patients whose specific cancer type is responsive to anthracyclines, provided they have adequate organ function. Special considerations and potential dose adjustments may be necessary for elderly patients, children, and those with mild liver impairment or significant prior cytotoxic therapy.

Contraindications (Should Not Use)	Special Precautions (Use with Caution)
Heart conditions: Severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, or previous maximum cumulative doses of anthracyclines.	History of heart disease, prior or concurrent radiation to the chest area.
Blood issues (IV use): Persistent myelosuppression (low blood cell counts) from previous treatments.	Active or dormant infections.
Liver issues (IV use): Severe hepatic impairment.	Mild to moderate hepatic impairment (dose reduction required).
Allergy: Hypersensitivity to doxorubicin or other anthracyclines.	Pregnancy or breastfeeding.

Patients must recover from acute toxicities of prior cytotoxic treatment, like stomatitis or myelosuppression, before starting Adriblastina. Due to the risk of irreversible cardiotoxicity, careful monitoring of cardiac function is essential before and throughout treatment.

Interactions with other medicines and products

Adriblastina (Doxorubicin) may interact with other medicinal products, with official warnings focusing on combinations that alter drug exposure or increase the risk of toxicity.

Formally Documented Interaction Patterns

Interaction Type	Interacting Substance(s)	Official Constraint/Effect
Contraindicated Combination	Trastuzumab	Co-administration is prohibited; Doxorubicin-based therapy must be avoided for up to 7 months after discontinuation.
Exposure Modification	Cyclosporine, Cimetidine, Verapamil, Labetalol	Can increase Doxorubicin plasma concentration, primarily through P-glycoprotein inhibition.
Exposure Modification	Phenobarbital, Phenytoin	May increase Doxorubicin clearance, potentially reducing systemic exposure.
Additive Toxicity Risk	Other Cardiotoxic Agents (e.g., Cyclophosphamide), Myelosuppressive Agents, Hepatotoxic Agents	Increases the risk of severe cardiotoxicity, myelosuppression, and liver toxicity.
Timing Restriction	Paclitaxel	Doxorubicin must be administered before Paclitaxel to prevent elevated drug levels.

Population-Specific Interaction Notes

Regulatory information notes that the toxic effects of additive hepatotoxic and myelosuppressive interactions are more pronounced in patients with pre-existing impaired liver function.

Genomic Integrity Disruption and Enzyme Poisoning

Adriblastina (Doxorubicin) primarily targets cellular Deoxyribonucleic Acid (DNA) and the enzyme Topoisomerase II Alpha ( TOP2 A) within the nucleus. The drug uses DNA intercalation to physically block replication and poisons TOP2 A, leading to an accumulation of irreversible DNA double-strand breaks (DSBs). This genomic catastrophe activates the DNA Damage Response (DDR), forcing the cell into irreversible cell cycle arrest that triggers programmed cell death (apoptosis).

Free Radical Generation and Mechanistic Constraints

A parallel mechanism involves redox cycling, primarily in the mitochondria, where the drug generates high levels of Reactive Oxygen Species (ROS). These toxic molecules inflict severe, non-specific oxidative stress damage to cellular components, further supporting the commitment of the cell to apoptosis and contributing to the overall physiological mechanism of cellular destruction. The drug's activity on the TOP2 B isoform in non-dividing cardiomyocytes establishes a crucial biological limitation, restricting the maximum cumulative dose that can be administered.

How Adriblastina is Used: Standard Administration Protocols

Adriblastina (doxorubicin hydrochloride) is administered under specific protocols focusing on the route, precise dosing, and scheduling. It is primarily given by intravenous (IV) injection or infusion for systemic use, although intravesical instillation is a route for localized administration in bladder conditions.

---

Dosing and Frequency

Regimen	Dose Range (based on body surface area)	Frequency	Cumulative Limit
Single Agent	60 mg/m^2 to 75 mg/m^2	Every 21 days	leq 550 mg/m^2 (Lifetime)
Combination	40 mg/m^2 to 75 mg/m^2	Every 21 to 28 days

Dose Adjustments

Specific dose reductions are established for patients with impaired hepatic function. For example, a 50% dose reduction is indicated when serum total bilirubin is between 1.2 mg/dL and 3 mg/dL. Lower doses or longer intervals are also considerations for older adults or heavily pretreated patients.

---

Preparation and Administration Specifics

The medication must be properly prepared prior to administration. Lyophilized powder forms must be reconstituted and diluted using specific solutions, such as 0.9% Sodium Chloride Injection. The diluted solution must be protected from light from preparation until the infusion is finished, and it is generally required to be used within one hour.

Intravenous administration is performed as a short injection, typically over 3 to 10 minutes, into a secure, free-flowing peripheral or central line. Treatment cycles are not initiated until the patient has recovered from acute toxicities of prior treatments, adhering strictly to the prescribed cyclic timing.

Recent Clinical Evidence and Research Focus

Adriblastina (Doxorubicin) is a key component in treatment regimens for various cancers, including breast cancer, lymphomas (Hodgkin and non-Hodgkin), sarcomas, and acute leukemias. Recent research and ongoing clinical trials aim to optimize its use by focusing on combination therapies and mitigating long-term risks.

Optimization and New Formulations

• Cardioprotection: A major focus involves strategies to reduce the risk of dose-dependent cardiotoxicity, which can lead to congestive heart failure. Cardioprotective agents, such as dexrazoxane, are studied for their potential to reduce cardiac injury without compromising the compound's anticancer properties.
• Liposomal Formulations: Nanotechnology-based delivery systems, such as liposomal doxorubicin, are being investigated. These formulations are associated with improved pharmacokinetics and have reported reduced cardiotoxicity compared to conventional formulations in clinical applications.

Combination and Long-Term Data

• Combination Therapies: The compound is frequently studied in combination with newer agents, including immune checkpoint inhibitors and targeted therapies, to evaluate whether an enhanced anti-cancer immune response may be observed.
• Survival Data in Breast Cancer: Meta-analyses of trials comparing doxorubicin-containing regimens versus non-doxorubicin regimens (e.g., CMF) in early breast cancer have assessed long-term outcomes like disease-free survival and overall survival over extended periods.
• Long-Term Risk: Studies tracking long-term survivors of Hodgkin lymphoma have shown that exposure to doxorubicin is associated with an increased risk of subsequent breast cancer in adolescent and adult female survivors, with the risk being dose-dependent. These findings emphasize the importance of extended follow-up and inform surveillance guidelines.

Common questions about Adriblastina (FAQ)

Q: What is Adriblastina and how does it work?

A: Adriblastina is a chemotherapy drug whose active substance is doxorubicin hydrochloride. It belongs to a group of medicines called anthracyclines.

It works by interfering with the genetic material (DNA and RNA) inside cancer cells, which prevents them from growing and dividing. This action ultimately leads to the death of the cancer cells.

---

Q: What is Adriblastina used to treat?

A: Adriblastina is used to treat a wide range of cancers. It may be used alone or in combination with other anti-cancer drugs as part of a chemotherapy regimen. The types of cancers it treats include:

• Acute leukemias (acute lymphocytic leukemia, acute myelogenous leukemia)
• Lymphomas (Hodgkin's disease and non-Hodgkin's lymphoma)
• Multiple myeloma
• Solid tumors such as breast cancer, lung cancer, ovarian cancer, stomach cancer, thyroid cancer, and sarcomas (e.g., osteosarcoma, Ewing's sarcoma, soft tissue sarcoma).

It is also sometimes used in the bladder to treat or prevent the recurrence of superficial bladder tumors.

---

Q: How is Adriblastina given?

A: Adriblastina is given as an intravenous infusion (into a vein) by a healthcare professional in a hospital or clinic setting. It is usually given slowly over a period of time, not as a rapid injection.

For some types of bladder tumors, it may be administered directly into the bladder using a catheter (this is called intravesical instillation).

---

Q: What are the most common side effects of Adriblastina?

A: The most common side effects relate to its effect on rapidly dividing cells and include:

• Bone marrow suppression: This leads to a decrease in blood cell counts, which can result in:
  • Neutropenia (low white blood cells, increasing the risk of infection).
  • Anemia (low red blood cells, causing fatigue).
  • Thrombocytopenia (low platelets, increasing the risk of bleeding).
• Gastrointestinal issues: Nausea, vomiting, diarrhea, and mouth sores (stomatitis or mucositis), which can progress to ulcers.
• Hair loss (alopecia): This is usually reversible after treatment ends.
• Fatigue and general weakness (asthenia).

Your healthcare team will monitor you closely for these effects during treatment.

---

Q: Is there a risk of heart damage with Adriblastina?

A: Yes, Adriblastina is known to cause cardiotoxicity (heart damage), which can sometimes lead to serious heart problems, including heart failure. This risk is typically related to the total amount (cumulative dose) of the drug received over a lifetime, but it can occur at lower doses.

Your doctor will assess your heart function with tests (such as an ECG or an echocardiogram) before you start treatment and periodically during your therapy to monitor for any changes. It is crucial to report any symptoms like shortness of breath, swelling of the legs or ankles, or a fast heartbeat to your doctor immediately.

The storage and disposal of Adriblastina (doxorubicin hydrochloride) must comply strictly with official regulatory requirements for cytotoxic agents.

Mandatory Storage Conditions

Requirement	Official Statement
Temperature	Store intact vials under refrigeration at 2°C to 8°C (36°F to 46°F).
Protection	The product must be protected from light during storage and through the entire infusion.
In-Use Stability	Once diluted for infusion, the solution must be used within one hour; otherwise, it must be discarded.
Special Handling	If refrigerated solution forms a gelled product, place it at room temperature (15 C to 30 C) for 2 to 4 hours to restore its mobile state.

Disposal and Safety

As a hazardous drug, personnel must follow specific anti-cancer drug handling procedures, including wearing protective gloves. Contact with skin must be immediately followed by thorough washing. Unused portions and all contaminated materials must be discarded according to local regulations for cytotoxic waste and should not be disposed of in household waste or wastewater. The medicine must also be stored out of the reach of children.